SG Americas Securities
PGNX

SG Americas Securities’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

SG Americas Securities’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,931
Closed -$68K – 3955
2020
Q1 		$68K Buy
+17,931
New +$77.3K ﹤0.01% 3112
2019
Q2 		– Sell
-44,136
Closed -$205K – 3605
2019
Q1 		$205K Buy
44,136
+31,144
+240% +$141K ﹤0.01% 2555
2018
Q4 		$55K Buy
+12,992
New +$66.2K ﹤0.01% 2814
2017
Q4 		– Sell
-14,530
Closed -$107K – 3826
2017
Q3 		$107K Buy
14,530
+4,057
+39% +$25.8K ﹤0.01% 3156
2017
Q2 		$71K Buy
+10,473
New +$77.3K ﹤0.01% 2983
2017
Q1 		– Sell
-26,951
Closed -$233K – 3676
2016
Q4 		$233K Buy
+26,951
New +$199K ﹤0.01% 2243
2015
Q4 		– Sell
-16,278
Closed -$93K – 3084
2015
Q3 		$93K Buy
+16,278
New +$125K ﹤0.01% 1898
2014
Q2 		– Sell
-36,759
Closed -$150K – 2779
2014
Q1 		$150K Buy
+36,759
New +$188K ﹤0.01% 2052
2013
Q4 		– Sell
-16,671
Closed -$84K – 3158
2013
Q3 		$84K Buy
+16,671
New +$90.4K ﹤0.01% 2704

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

SG Americas Securities's PGNX Position: Q2 2020 in Review

SG Americas Securities sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 17,931 shares — an estimated $68K sold.

SG Americas Securities first reported a position in PGNX in Q3 2013 and held it in 9 quarters. The position peaked at $233K in Q4 2016. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • SG Americas Securities reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • SG Americas Securities sold 17,931 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $68K.
  • SG Americas Securities first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 9 quarters.
  • SG Americas Securities's Progenics Pharmaceuticals Inc position peaked at $233K in Q4 2016.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on SG Americas Securities's 13F filing for Q2 2020, filed 20 Jul 2020.